CLRB saw its Momentum Indicator move below the 0 level on September 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 79 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CLRB turned negative on September 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CLRB entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for CLRB's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +14.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLRB advanced for three days, in 184 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CLRB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.370) is normal, around the industry mean (2.973). P/E Ratio (-0.529) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CLRB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Moving Average Convergence Divergence (MACD) for QTTB turned positive on October 08, 2026. Looking at past instances where QTTB's MACD turned positive, the stock continued to rise in 34 of 38 cases over the following month. The odds of a continued upward trend are 89%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where QTTB's RSI Oscillator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on QTTB as a result. In 75 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +2.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTTB advanced for three days, in 212 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
QTTB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTTB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for QTTB entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. QTTB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.474) is normal, around the industry mean (2.973). P/E Ratio (2.803) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (3.034) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 99 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTTB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CLRB | QTTB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 46 Fair valued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 99 | |
SMR RATING 1..100 | 99 | 16 | |
PRICE GROWTH RATING 1..100 | 93 | 41 | |
P/E GROWTH RATING 1..100 | 8 | 23 | |
SEASONALITY SCORE 1..100 | 85 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CLRB's Valuation (46) in the Biotechnology industry is in the same range as QTTB (76) in the null industry. This means that CLRB’s stock grew similarly to QTTB’s over the last 12 months.
QTTB's Profit vs Risk Rating (99) in the null industry is in the same range as CLRB (100) in the Biotechnology industry. This means that QTTB’s stock grew similarly to CLRB’s over the last 12 months.
QTTB's SMR Rating (16) in the null industry is significantly better than the same rating for CLRB (99) in the Biotechnology industry. This means that QTTB’s stock grew significantly faster than CLRB’s over the last 12 months.
QTTB's Price Growth Rating (41) in the null industry is somewhat better than the same rating for CLRB (93) in the Biotechnology industry. This means that QTTB’s stock grew somewhat faster than CLRB’s over the last 12 months.
CLRB's P/E Growth Rating (8) in the Biotechnology industry is in the same range as QTTB (23) in the null industry. This means that CLRB’s stock grew similarly to QTTB’s over the last 12 months.
| CLRB | QTTB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 77% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 86% |
| Momentum ODDS (%) | 2 days ago 90% | 1 day ago 81% |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 89% |
| TrendWeek ODDS (%) | 1 day ago 89% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 88% |
| Advances ODDS (%) | 2 days ago 81% | 1 day ago 87% |
| Declines ODDS (%) | 4 days ago 87% | 7 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLRB’s FA Score shows that 1 FA rating(s) are green while QTTB’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLRB’s TA Score shows that 4 TA indicator(s) are bullish while QTTB’s TA Score has 5 bullish TA indicator(s).
CLRB (@Biotechnology) experienced а -1.68% price change this week, while QTTB (@Biotechnology) price change was +13.26% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
CLRB is expected to report earnings on Nov 12, 2026.
QTTB is expected to report earnings on Nov 12, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, CLRB has been loosely correlated with QTTB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if CLRB jumps, then QTTB could also see price increases.
| Ticker / NAME | Correlation To CLRB | 1D Price Change % | ||
|---|---|---|---|---|
| CLRB | 100% | -8.59% | ||
| QTTB - CLRB | 62% Loosely correlated | +1.50% | ||
| ADCT - CLRB | 43% Loosely correlated | +6.67% | ||
| RKTO - CLRB | 42% Loosely correlated | +1.39% | ||
| OGEN - CLRB | 41% Loosely correlated | -1.82% | ||
| ANAB - CLRB | 40% Loosely correlated | +0.33% | ||
More | ||||
A.I.dvisor indicates that over the last year, QTTB has been loosely correlated with CLRB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if QTTB jumps, then CLRB could also see price increases.
| Ticker / NAME | Correlation To QTTB | 1D Price Change % | ||
|---|---|---|---|---|
| QTTB | 100% | +1.50% | ||
| CLRB - QTTB | 62% Loosely correlated | -8.59% | ||
| MESO - QTTB | 51% Loosely correlated | -2.18% | ||
| STOK - QTTB | 49% Loosely correlated | +0.08% | ||
| IBRX - QTTB | 40% Loosely correlated | -3.82% | ||
| ANAB - QTTB | 39% Loosely correlated | +0.33% | ||
More | ||||